MTOR and adenocarcinoma: Intriguingly, the mTOR/glycolysis combined pathway score was significantly lower in NEPC compared to adenocarcinoma, suggesting that this metabolic dysregulation may represent a distinct mechanism of aggressive disease from the transition to the androgen‐independent NEPC phenotype.